Tab 2: Expression of survivin in breast cancer in relation to prognosis and outcome.
| Author/yr./ reference | Assay | Patient No. and positive rate | Outcome | - = + |
| Tanaka K/2000/ (66) | IHC | 167/70.7% | With worse outcome in breast carcinoma. | - |
| Nasu S/2002/ (63) | RT-PCR | 37/41 (90.2%) | No significant association with clinicopathological factors, survivin mRNA is a useful diagnostic marker for breast cancer. | - |
| Kennedy/2003/ (67) | pAb | 293/60% | Nuclear staining of survivin is an independent prognostic indicator of good prognosis both in relapse-free and overall survival | + |
| O'Driscoll L/2003/ (68) | RT-PCR | 72/106/68% | No significant association was found between the expression of wild-type or the splice variants and disease free or overall survival. | = |
| Chu JS/2004/ (69) | IHC | 226/59.3% | Correlate with clinicopathologic parameters, It does not have significance as a marker in predicting overall or disease-free survival. | = |
| Span PN/2004 (70) | mRNA | 275/100% | Poor prognosis, positive relationship with grade higher in ductal rather than in lobular breast cancers | - |
| Ryan B/2005/ (36) | sq RT-PCR | 156/93.6% | Survivin andΔEx3 positively correlated with apoptosis | - |
| Barnes N/2006/ (71) | IHC | DCIS (n=161/73%) IBC (n=58 /74%) | Correlated to DCIS recurrence. | - |
| Ryan BM/2006/ (36) | ELISA | 420/90% | Independent prognostic factor, with a significantly worse disease-free survival and overall survival | - |
| Kostadima L/2006/ (39) | RT-PCR | 263/272 (90%) | Associated with adverse clinicopathologic and molecular characteristics of node-positive primary breast cancer but do not predict patient outcome. | = |
| Sohn DM /2006 (5) | IHC | 52/80 (65%) | The expression of cytoplasmic survivin was common in breast cancer and could be both a useful diagnostic marker and an important source of prognostic information. with poor prognosis | - |
| Span PN/2006/ (72) | qRT-PCR | 275 | Total survivin, survivin 2alpha, and survivin-3B were associated with poor relapse-free survival | - |
| Hinnis AR/2007/ (73) | IHC | 165 | With shorter survival and adverse outcomes. | - |
| Al-Joudi FS/2007 (74) | IHC | 260/382 (68.1%) | Aid in diagnosis, confirm malignancy, and assess the disease progress and response to therapy. | - |
| Al-Joudi FS/2007/ (75) | IHC | 382 | Tumor histological grades and tumor size and lymph node involvement. | - |
| Nassar A/2008 (76) | IHC | 30/37 (80%) | Correlate with overall survival | - |
| Brennan DJ/2008/ (77) | IHC | 102 | Nuclear survivin is a poor prognostic marker in breast cancer. | - |
| Nassar A/2008/ (78) | IHC | 91/84% | Correlate with poor prognostic parameters, but not with outcome | - |
| Tsai WC/2008/ (1) | IHC | 290 | Higher expressions of matriptase and survivin correlate significantly with clinicopathological parameters in breast cancer and the malignant potential in premalignant lesions. In addition, higher survivin expression had poorer prognosis of breast IDC cases. | - |
| Fuzhong T/2008/ (79) | SDS-PAGE, western-immunoblotting, IHC and mAb | The patients have high response rate of low expression of survivin survivin is an important predictive factor for effectiveness of neoadjuvant chemotherapy with TE regimen in locally advanced breast cancer | - |
mAb, monoclonal antibody, pAb, polyclonal antibody, sq RT-PCR, semiquantitative reverse transcriptase polymerase chain reaction, IHC, immunohistochemistry, CNR, cytoplasmic to-nuclear ratio. –, negative prognosis, =, irrespective, +, positive prognosis.